Homocysteine levels in takayasu arteritis-A risk factor for arterial ischemic events

Journal of Rheumatology

Volumn 40, Issue 3, 2013, Pages 303-308

  De Souza, Alexandre Wagner Silva ^a   Serrano De Lima, Carla ^a   Oliveira, Ana Cecilia Diniz ^a   Machado, Luiz Samuel Gomes ^a   Pinheiro, Frederico Augusto Gurgel ^a   Hix, Sonia ^a   D'Almeida, Vania ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Arterial inflammation; Homocysteine; Takayasu arteritis; Thrombosis

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYSTEINE; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE;

ADULT; AMINO ACID BLOOD LEVEL; AORTA ARCH SYNDROME; ARTERY DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYSTEINE BLOOD LEVEL; DIET RESTRICTION; DISEASE ACTIVITY; DRUG USE; ENZYME ACTIVITY; FEMALE; HOMOCYSTEINE BLOOD LEVEL; HUMAN; ISCHEMIA; PRESCRIPTION; PRIORITY JOURNAL; REMISSION;

ADULT; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; CYSTEINE; FEMALE; HOMOCYSTEINE; HUMANS; MIDDLE AGED; RISK FACTORS; TAKAYASU ARTERITIS;

EID: 84874821060     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121073     Document Type: Article

References (38)

1. Mason JC. Takayasu arteritis - Advances in diagnosis and management. Nat Rev Rheumatol 2010;6:406-15.
2. Numano F, Okawara M, Inomata H, Kobayashi Y. Takayasu's arteritis. Lancet 2000;356:1023-5.
3. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med 1994;120:919-29.
4. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007;56:1000-9.
5. Jain S, Kumari S, Ganguly NK, Sharma BK. Current status of Takayasu arteritis in India. Int J Cardiol 1996;54 Suppl:S111-6.
6. Bicakcigil M, Aksu K, Kamali S, Ozbalkan Z, Ates A, Karadag O, et al. Takayasu's arteritis in Turkey - Clinical and angiographic features of 248 patients. Clin Exp Rheumatol 2009;27 Suppl 52:S59-64.
7. Arnaud L, Haroche J, Limal N, Toledano D, Gambotti L, Costedoat Chalumeau N, et al. Takayasu arteritis in France: A single-center retrospective study of 82 cases comparing white, North African, and black patients. Medicine 2010;89:1-17.
8. de Souza AW, Machado NP, Pereira VM, Arraes AE, Reis Neto ET, Mariz HA, et al. Antiplatelet therapy for the prevention of arterial ischemic events in Takayasu arteritis. Circ J 2010;74:1236-41.
9. Akazawa H, Ikeda U, Yamamoto K, Kuroda T, Shimada K. Hypercoagulable state in patients with Takayasu's arteritis. Thromb Haemost 1996;75:712-6.
10. Numano F, Maruyama Y, Koyama T, Numano F. Antiaggregative aspirin dosage at the affected vessel wall. Angiology 1986; 37:695-701.
11. Kasuya N, Kishi Y, Isobe M, Yoshida M, Numano F. P-selectin expression, but not GPIIb/IIIa activation, is enhanced in the inflammatory stage of Takayasu's arteritis. Circ J 2006;70:600-4.
12. Watanabe T, Kishi Y, Numano F, Isobe M. Enhanced platelet sensitivity to prostacyclin in patients in an active stage of Takayasu arteritis. Thromb Res 2001;104:77-83.
13. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
14. Brustolin S, Giugliani R, Félix TM. Genetics of homocysteine metabolism and associated disorders. Braz J Med Biol Res 2010;43:1-7.
15. Desouza C, Keebler M, McNamara DB, Fonseca V. Drugs affecting homocysteine metabolism: Impact on cardiovascular risk. Drugs 2002;62:605-16.
16. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002;288:2015-22.
17. Homocysteine studies collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002;288:2015-22.
18. Yilmaz N. Relationship between paraoxonase and homocysteine: Crossroads of oxidative stress. Arch Med Sci 2012;8:138-53.
19. Patterson RA, Lamb DJ, Leake DS. Mechanisms by which cysteine can inhibit or promote the oxidation of low density lipoprotein by copper. Atherosclerosis 2003;169:87-94.
20. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129-34.
21. Thygenesen K, Apert JS, White HD, Joint ESC/ACCF/AHA/WHF. Task force for redefinition of myocardial infarction. Universal definition of myocardial infarction. Circulation 2007;116:2634-53.
22. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D, et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: A statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003;108:2543-9.
23. Stroke - 1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. Stroke 1989;20:1407-31.
24. Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al. Definition and evaluation of transient ischemic attack: A scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009;40:2276-93.
25. American Gastroenterological Association. Medical position statement: Guidelines on intestinal ischemia. Gastroenterology 2000;118:951-3.
26. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45 Suppl S:S5-67.
27. Pfeiffer CM, Huff DL, Gunter EW. Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting. Clin Chem 1999;45:290-2.
28. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991;19:100-6.
29. De Geest B, Stengel D, Landeloos M, Lox M, Le Gat L, Collen D, et al. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. Arterioscler Thromb Vasc Biol 2000;20:E68-75.
30. Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 1996;54 Suppl:S155-63.
31. Morgan SL, Baggott JE. Folate supplementation during methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2010;28 Suppl 61:S102-9.
32. Seyahi E, Ugurlu S, Cumali R, Balci H, Seyahi N, Yurdakul S, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 2006;65:1202-7.
33. Martinez-Taboada VM, Bartolome MJ, Fernandez-Gonzalez MD, Blanco R, Rodriguez-Valverde V, Lopez-Hoyos M. Homocysteine levels in polymyalgia rheumatic and giant cell arteritis: Influence of corticosteroid therapy. Rheumatology 2003;42:1055-61.
34. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37485 individuals. Ann Intern Med 2010;170:1622-31.
35. Espinola-Zavaleta N, Soto-López ME, Carreón-Torres E, Gamboa R, Mejía AM, Márquez-Velasco R, et al. Altered flow-mediated vasodilatation, low paraoxonase-1 activity, and abnormal high-density lipoprotein subclass distribution in Takayasu's arteritis. Circ J 2009;73:760-6.
36. Holven KB, Aukrust P, Retterstøl K, Otterdal K, Bjerkeli V, Ose L, et al. The antiatherogenic function of HDL is impaired in hyperhomocysteinemic subjects. J Nutr 2008;138:2070-5.
37. El-Khairy L, Ueland PM, Nygård O, Refsum H, Vollset SE. Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: The Hordaland Homocysteine Study. Am J Clin Nutr 1999;70:1016-24.
38. El-Khairy L, Ueland PM, Refsum H, Graham IM, Vollset SE; European Concerted Action Project. Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project. Circulation 2001;103:2544-9.